Using light therapy to treat skin cancer from breast cancer
An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
This study is looking at a new way to treat skin cancer from breast cancer using a special light therapy that targets tumors while being gentle on healthy skin, and it's designed for patients who have stable cancer but are dealing with bothersome skin issues.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kintara Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project ID | NIH-10877852 on NIH RePORTER |
What this research studies
This research investigates a new treatment for cutaneous metastatic breast cancer (CMBC) using a method called photodynamic therapy (PDT). In this approach, a special drug is injected into the body, which collects at tumor sites and is then activated by a laser to destroy cancer cells while sparing surrounding healthy tissue. The study aims to test a lower dosage of this drug to minimize side effects, which have been problematic in previous trials. By focusing on patients with stable systemic disease and symptomatic skin lesions, the research seeks to improve treatment outcomes and patient comfort.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with symptomatic cutaneous lesions from metastatic breast cancer who have stable systemic disease.
Not a fit: Patients with aggressive systemic disease or those who do not have cutaneous lesions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and less harmful treatment option for patients suffering from cutaneous metastatic breast cancer.
How similar studies have performed: Previous studies using photodynamic therapy have shown promising results, indicating that this approach may be effective for treating similar conditions.
Where this research is happening
San Diego, UNITED STATES
- Kintara Therapeutics, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Brown, Dennis — Kintara Therapeutics, INC.
- Study coordinator: Brown, Dennis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.